hGH fragment 176–191 analog
AOD-9604
Cited range Metabolic fragment
What it is
AOD-9604 is a modified fragment of the C-terminus of human growth hormone, developed as a metabolic candidate rather than a growth agent. It is not recombinant GH.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- A modified slice of the fat-burning tail of growth hormone, designed to skip GH’s growth and sugar effects.
- People want lipolysis — help the body release stored fat — without IGF spikes.
- Clinical attempts have been mixed; it is not an approved fat-loss drug in the US.
- Think of it as a “GH fat fragment” experiment, not a replacement for diet.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Proposed stimulation of lipolysis and inhibition of lipogenesis in adipose models, with much less IGF-1 movement than intact GH in the developer narrative. Human results were mixed enough that it never became a mainstream approved obesity drug.
Possible side effects / caveats
Generally described as milder than intact GH; injection-site issues and uncertain long-term metabolic data remain. Do not treat it as “safe GH.”
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Cited range | 250–500 mcg daily | Once daily SC, often morning fasted in secondary sources | Dominant catalog window |